Philip Goulder, M.D., Ph.D.

Lab Info:

Principal Investigator: Philip Goulder, M.D., Ph.D.

Phone: 01865 281884

Email: philip.goulder@paediatrics.ox.ac.uk

Category: Associate Members

Philip Goulder obtained his first degree in Zoology at Oxford University in 1982, and then qualified in Medicine at Cambridge University in 1986, before completing training in Paediatrics through appointments at Edinburgh, Oxford, Duke University Medical Center in the US and the Royal Hospital for Sick Children in Melbourne, Australia.

His investigative career started in 1993, undertaking a DPhil under the supervision of Andrew McMichael. This work demonstrated the central role of HLA-B*27 and HLA-B*57 in immune control of HIV infection, and of cytotoxic T lymphocyte (CTL) escape in HIV pathogenesis (Goulder et al, AIDS Res Hum Retr, 1996; Goulder et al, Nat Med, 1997).

During a post-doc at Massachusetts General Hospital, Boston, under the mentorship of Bruce Walker, he studied mother-to-child transmission of HIV at Boston Children’s Hospital and showed that CTL escape mutants can be transmitted stably and significantly impact disease progression in the recipient (Goulder et al, Nature, 2001).

In order to focus on the populations and clade of virus most relevant to vaccine development, Goulder initiated research collaborations with Hoosen Coovadia and colleagues at the University of KwaZulu-Natal (UKZN), Durban, South Africa in 1998.

In 2001, Coovadia, Walker and Goulder were awarded a special grant by the Doris Duke Charitable Foundation for the construction of the Doris Duke Medical Research Institute (DDMRI) at UKZN, the official opening of which was presided over by Jacob Zuma in 2003. The HIV Pathogenesis Programme (HPP), based within the DDMRI, provides state-of-the-art laboratory facilities to enable basic and translational research projects to be undertaken at a site at the heart of the global HIV epidemic. To date more than 50 publications have resulted from work undertaken at the HPP, including high impact contributions to Nature and Nature Medicine (eg Kiepiela et al, Nature, 2004; Leslie et al, Nature Medicine, 2004; Kiepiela et al, Nature Medicine, 2007, Kawashima et al, Nature, 2009) on each of which Goulder was lead senior author.

Goulder’s research work continues to focus on the South African HIV epidemic. Through long-established collaborations in Durban and Kimberley, these studies in particular seek to define: the immune responses that are effective in control of HIV infection; the impact of HLA-mediated selection pressure on HIV at the individual and population level; the mechanisms of HIV non-pathogenicity; the nature and consequences of ontogeny of the virus-specific immune response; and finally the prospects for interventions including antiretroviral therapy, alone or in combination with broadly neutralising antibodies and/or T-cell vaccines, to achieve HIV eradication. Recently, in 2015, Goulder received a Wellcome Trust Senior Investigator Award to investigate the potential for HIV cure in specific groups of infected children.